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5ABSTRACT
The baculovirus expression vector system (BEVS) was used for the
expression of several different constructs encoding the rubella virus (RV)
structural proteins. From a construct encoding the structural p110
polyprotein the E1 protein was produced and purified using
immunoaffinity chromatography. The purified protein was shown in an
ELISA study to have a similar antigenicity to authentic RV. The ability of
the purified E1 to react with human RV specific IgM antibodies was
compared with authentic RV in a correlation assay, using time-resolved
fluorescence (TR-FIA). The TR-FIA analysis showed a positive
correlation of r=0,843.
The protein production level was scaled-up into a 10 l bioreactor,
and soluble forms of the E1 and E2 proteins, as well as a his6 tagged form
of the capsid protein was produced. The E1 protein was purified to
homogeneity using lectin affinity chromatography and the his6 tagged
capsid protein was purified using immobilized metal-ion affinity
chromatography (IMAC). The capsid protein was further studied in
surface plasmon resonance (SPR) experiments using the BIAcoreTM
equipment and the interaction between the capsid and a specific antibody
could be detected in real-time.
An E1 construct containing the his6 tag at the C-terminal and an N-
terminal FLAGTM-tag (Eastman Kodak Co., New Haven, CT) was
produced. The E1 construct was purified using IMAC and Anti-FLAG
M1 Affinity Chromatography. The purified protein was studied using the
BIAcoreTM equipment in a setup where the Ca2+ dependent binding of an
antibody specific for the FLAG-tag was used for visualization of the
sensitivity of the assay. The impact of the described research for
diagnostic application and as providing tools for RV research is discussed.
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8ABBREVIATIONS
AP alkaline phosphatase
BEVS baculovirus expression vector system
BSA bovine serum albumin
C capsid protein
CRS congenital rubella syndrome
DNA deoxyribonucleic acid
E1 envelope protein 1
E2 envelope protein 2
ECV extra-cellular virus
EDTA ethylene diaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
ER endoplasmic reticulum
FLAG eight amino acid affinity epitope tag
HRP horseradish peroxidase
IgG immunoglobulin G
IgM immunoglobulin M
M1 FLAG epitope-specific monoclonal antibody 1
MOI multiplicity of infection
NSP nonstructural protein
o/n over night
ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
PFU plaque forming units
p.p. post infection
p.p. post planting
RNA ribonucleic acid
RRV ross river virus
RV rubella virus
RT room temperature (approximately 20°C)
SDS sodium dodecyl sulfate
SFV semliki forest virus
SIN sindbis virus
SPR surface plasmon resonance
TR-FIA time-resolved fluoroimmunoassay
VLP virus-like particle
91. INTRODUCTION
Viruses were first discovered by mankind just over 100 years ago. In
the latter half of the 19th century many disease causing bacteria were
identified. However, several diseases were shown not to have a bacterial
origin. This lead to the discovery of a new infectious agent, referred to as virus
in the work of Ivanovsky, Beijernick, Loeffler and Froch, between 1892 and
1898. Viruses were defined as small “organisms” capable of replication in the
presence of a host cell. In the 1930s viruses were for the first time visualized
by Kausche using electron microscopy. The virus particle was shown to consist
of either a RNA or a DNA genome encapsidated by several copies of a capsid
protein, and for some viruses also a lipid-bilayer containing viral envelope
proteins. By 1977 mankind's knowledge of viruses had led to the total
eradication of smallpox, being the first "organism" eliminated on purpose by
man. Today we have a broad knowledge of the structure and the biology of
several viruses. We also have a recombinant virus vaccine (hepatitis B virus)
and the process of eliminating several viruses is ongoing. In this century we
will also see viruses serve as important tools in gene technology. Only time
will tell if viruses, often called the ultimate parasite, will one day serve  the
purposes of their former hosts (for review see Oldstone and Levine, 2000).
1.1 Togaviridae
The family Togaviridae contains  two genera, the Alphaviruses and the
Rubivirus. The Alphavirus genus consists of at least 26 members, the most
studied being Semliki Forest virus (SFV), Sindbis virus (SIN) and Ross River
virus (RRV). Rubella virus (RV) remains the sole member of the Rubivirus
genus (for classification see; Matthews, 1982) (Fig. 1.). The Alphaviruses are
arguably the best characterized enveloped animal viruses today, whereas  the
molecular biology of RV has not been as thoroughly studied.. Alphavirus
crystals have also been obtained (Harrison et al., 1992).
All togaviruses are lipid enveloped small positive stranded RNA
viruses with a diameter of approximately 70 nm. The positive stranded genome
consists of around 10 000 nucleotides and has one open reading frame (ORF)
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encoding the nonstructural proteins (NSPs) and one ORF for a subgenomic
RNA encoding the structural proteins. The NSP-ORF has been shown to
encode for two proteins in the case of RV and four proteins in the Alphavirus
genus (Fig 2.). Similar transferase, helicase and proteinase regions have been
identified in all members of the Togaviridae, as well as motifs of unknown
function. Despite a similar gene arrangement, sequence analysis has  reveled
that RV is only distantly related to the Alphaviruses (for review see; Frey
1994; Strauss and Strauss 1994).
The positive stranded RNA genome of the Togaviridae viruses is
encapsulated by a capsid. The capsid core has a diameter of 30-35 nm in RV
and 38-40 nm in Alphaviruses. The RV capsid has been suggested to have a
T = 3 icosahedral symmetry, whereas Alphaviruses have a T = 4 symmetry (for
review see; Frey 1994; Strauss and Strauss 1994). Residues for interaction
between the envelope proteins and the nucleocapsid have also been identified
S in d b is  v iru s
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E n ce p h a lit is  v iru s
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Figure 1. Classification of the Togaviridae genus, based on sequence data. The Alphavirus
family consist of 26 or more different viruses, whereas rubella virus is the sole member of
the Rubivirus family.
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in Alphaviruses (Skoging et al., 1996; Owen and Kuhn, 1997), and recently
similar studies has been performed for the RV (Yao and Gillam, 1999).
The viral lipid envelope of the Togaviridae members is composed of
lipids from the host-cell and the virus-specific envelope glycoproteins, E1 and
E2. These proteins contain an intra-membrane part, a single membrane
spanning region and a large extra-membrane part. Together they form
glycosylated spike heteromeres on the virus surface. Alphaviruses may also
contain other membrane proteins e.g. E3 and 6K in SFV.
NH2-P1234-COOH
5 3
RNA 11445
C(267), E3(66), E2(422), 6K(60), E1(438)
NH2- C-p62-6K-E1-COOH
Nsp1(537), Nsp2(798), Nsp3(482), Nsp4(614)
Figure 2. Translation and processing of the two open reading frames of Semliki Forest virus. The
size of the proteins are shown as in brackets, as number of amino acids.
-Translation
-Proteolytic processing
-Translation from
 26S subgenomic
-Proteolytic processing
26S RNA
-Replication
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The budding of Alphaviruses and their structure-function relationships
have been studied in detail (reviewed in Helenius, 1995; Strauss et al., 1995;
and Garoff et al., 1998). Here, a striking difference between the RV and the
Alphaviruses has been uncovered. Whereas Alphaviruses bud from the cell
membrane, RV matures from intracellular membranes (Baron and Forsell,
1991; Hobman et al., 1993). In addition, the budding process of RV does not,
in contrast to Alphaviruses, seam to be driven by interactions between the E1
and the capsid (Garbutt et al., 1999). Several host-cell receptors have been
detected for the Alphaviruses whereas similar studies have failed to identify
any RV specific receptors (Nath et al., 1989; Wang et al., 1992). Another
striking difference is the kinetics of the replication cycle. Cells infected with
Alphaviruses reach a maximum virus production 4 – 8 h after infection
(Kääriäinen and Söderlund, 1978), whereas RV has a long latent period and
reaches a maximum 24 – 48 h after infection. (Hemphill et al., 1988).
Since Alphaviruses have a large host-cell range and are relatively easy and
rapid to grow, they have become very useful viral model systems. Many of the
viral intracellular mechanisms as well as structural aspects have been first
identified among Alphaviruses. Today, Alphaviruses have also found
applications as expression vectors and in gene therapy (Garoff and Li 1998a).
Many of the basic questions resolved for the Alphaviruses remain to be solved
for RV. Clearly, the differences between the Alphaviruses and RV, mean that
assumptions cannot be made about RV based on data derived from any of the
Alphaviruses. Since RV is a human pathogen many techniques for detecting
RV infection have however been developed.
1.2 The Rubella Virus
The RNA genome of RV is 9756 nucleotides long excluding a "cap"-
structure and a poly(A) tract (Dominguez et al., 1990). The 5'- two-thirds of
the genome encodes the nonstructural proteins (NSPs), and the 3' third encodes
the structural proteins. The nonstructural proteins are translated from the
genomic RNA as a 200 kDa precursor polyprotein. This polyprotein is cleaved
into two NSPs a 150 kDa polypeptide (P150) and a 90 kDa polypeptide (P90)
(Forng and Frey, 1995). The order of the NSPs within their open reading frame
(ORF) is NH2 - P150 - P90- COOH and the cleavage is mediated by a protease
activity within the P200 (Marr et al., 1994). The two NSPs are thought to form,
together with host factors, a complex for RNA replication.
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The viral RNA serves as a template for the production of a subgenomic
RNA, which when translated gives rise to a polypeptide precursor (p110) for
the structural proteins. The p110 is cleaved during translocation into the ER,
giving rise to a 33 kDa capsid protein (C) and two envelope glycoproteins, E2
(42-47 kDa) and E1 (58 kDa) (Oker-Blom et al., 1983; Kalkkinen et al., 1984:
Oker-Blom 1984) (Fig. 3.). The C protein forms a 30-35 nm core interacting
with and encapsulating the virus genome (Liu et al., 1996). The envelope
glycoproteins E1 and E2 both have a hydrophobic transmembrane segment
anchoring them in the lipid bilayer originating from the host-cell. This lipid
bilayer forms a viral envelope of approximately 60 nm in diameter, with E1
and E2 heteromer spike projections of 5-8 nm facing out from the surface
(reviewed in Frey, 1994) (Fig. 4.).
5’ 3’
RNA 9756 nucleotides
Figure 3. Translation and processing of the two open reading frames of rubella virus.
NH2 - P200- COOH
C - E2-E1
NH2 - p110 - COOH
P150 - P90
150 kDa 90 kDa 33
kDa
42-
47
58 kDa
24S subgenomic RNA
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The C protein has been shown to consist of two subtypes with pI values
of 8.8 and 9.5. This could be due to differential phosphorylation (Waxham and
Wolinsky, 1985). In the virus capsid, the C protein is present as a disulfide
linked dimer (Baron and Forsell, 1991). Within the p110 precursor the
carboxy-terminal region of the capsid protein functions as the signal sequence
for the E2 protein (Suomalainen et al. 1990).
The E2 protein is heavily glycosylated and 30-40 % of the molecular
mass is carbohydrate. This heavy and heterologous glycosylation makes the E2
molecular mass vary between 42 and 47 kDa . However, the major part of the
protein seems to be either 42 or 47 kDa in size (Oker-Blom et al., 1983). Both
the E1 and the E2 proteins have N-linked glycans, whereas only the E2 protein
has O-linked glycans (Qiu et al., 1992). pI values of the different forms of the
E2 protein have been reported ranging from 5.0 to 8.0. (Waxham and
Wolinsky, 1985). Near the carboxy terminus the E2 protein has a cluster of
hydrophobic amino acids anchoring it to the lipidmembrane. The putative
transmembrane region is followed by eight amino acids and the signal
sequence for the E1 protein.
RNA genome
capsid
lipid bilayer
E1 E2
Figure 4. Schematic drawing of a section of RV, showing the characteristics of an
enveloped virus.
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The E1 protein is thought to have a uniform glycosylation pattern, and
to interact with the E2 protein to form heterodimers on the virus surface (Yang
et al., 1998). The E1:E2 ratio on the surface of the virus is still not
convincingly determined, although a 1:1 ratio seams quite possible. At the
carboxy terminus the E1 has a putative transmembrane region followed by a 13
amino acid stretch, thought to be on the interior of the lipid bilayer.
Most enveloped animal viruses enter the cell by receptor mediated
endosytosis. For RV no cellular receptor has yet been found, although some
evidence for the importance of cellular lipids has been shown (Mastromarino et
al., 1990). Although attachment of RV to its host cells is rapid, internalization
is slow (Petruzziello et al., 1996).
The NSPs are translated from the 5' region of the viral RNA, and a
negative-polarity RNA is synthesized to function solely as a template for
synthesis of positive stranded RNA. The regulation of RNA synthesis is based
on sequence homology studies thought to function essentially as in the
Alphaviruses . P150 is thought to contain methyltransferase and protease
activities, and P90 is suggested to contain helicase and RNA polymerase
functions (Dominguez et al., 1990; Marr et al., 1994).
The structural proteins are modified following synthesis. The C protein
forms dimers and is membrane associated at the time of capsid formation. The
C protein is present both in the ER and the Golgi probably due to an
association between the C and the E2 protein. The envelope glycoproteins are
detectable in the ER, Golgi, intracellular vacuoles and on the cell surface, all of
which have been thought to be the site of virus budding. Dimerization between
the E1 and the E2 has been shown to be important for protein transport from
ER to Golgi, indicating that the assembly of the virus occurs before arrival to
the plasma membrane (Baron et al., 1992; Hobman et al., 1994a; Hobman et
al., 1995). The E2 protein has been shown to contain a Golgi retention signal
within the transmembrane region whereas an ER retention signal has been
found in the transmembrane and the cytoplasmic domain of the E1 protein
(Hobman et al., 1997).
Studies using virus-like particles (VLPs) containing the RV structural proteins
have revealed that the transmembrane and the cytoplasmic parts of E2 and E1
are required for viral assembly. Interactions between the capsid and the
cytoplasmic part of E1 does, however, not seem to be important for the viral
budding process (Garbutt et. al. 1999). Based on electron microscopic studies
the primary site for the viral budding process has been shown to be
cytoplasmic membranes. The lipid content of the virion envelope also shows
16
similarities to intracellular membranes rather than the plasma membrane
(reviewed in Frey, 1994).
1.3 Medical Significance of Rubella Virus
Infection caused by RV usually gives rise to a mild self-limited disease
called rubella or German measles. The symptoms of rubella are a mild rash,
low-grade fever and a sore throat. Often an infection can occur without
detectable symptoms. The most prominent feature of the disease is the rash
giving rise to the name of the disease. However, if this disease is acquired
during the first trimester of pregnancy, severe fetal damage may occur.
Infections occurring before the 16th week of pregnancy shows some disease
related consequences in 67-85% of the fetuses. The broad range of clinical
consequences acquired with fetal infection are called; Congenital Rubella
Syndrome (CRS). In most cases (80 %) fetal infection is found to give rise to
neuronal damage, sometimes expressed as mental retardation (reviewed in
Wolinsky 1990).
Among adult females joint symptoms are reported for more than 50%
of patients with rubella. Among children, males and vaccinated patients, the
symptoms are more rare. The joint disease is usually of a mild and transient
nature. In some patients chronic arthritis has also been reported following RV
infection (Ford et al., 1992). RV specific antibodies and in some cases RV
RNA (from synovial fluid cells) can also be detected from groups of patients
with chronic joint diseases (Bosma et al., 1998). The mechanism and
importance of RV in these chronic diseases remains to be resolved.
In cell cultures RV has been shown to induce apoptosis in infected mammalian
cells. Apoptosis naturally occurs as a protection system to kill damaged cells,
and has been shown to occur during various viral infections. For RV infections
apoptosis has not been demonstrated in human cells and the role of apoptosis
in severe rubella complications has not been shown (Pugachev and Frey, 1998:
Megyeri et al. ,1999).
Vaccination against rubella, with a live attenuated virus, was started in
the mid-1970:s in most industrial countries. Several improvements in the
vaccine and the vaccination program has led to a near complete elimination of
rubella from the Western world. In under developed countries and crisis
regions rubella is still seen as a major problem. In Finland we have today more
than 95 % of the population vaccinated against rubella and the current opinion
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is that our vaccination program should prevent us from outbreaks, thus keeping
the annual cases of rubella to fewer than 30 per year (Peltola et al., 1994).
1.4 Diagnosis of Rubella Virus Infection
Since rubella is a mild and sometimes asymptomatic disease a laboratory test is
needed for the diagnosis. Since CRS is very serious and linked to the early
trimester of pregnancy, rubella diagnosis should be reliable and rapid. The first
method to meet this criterion was the heamagglutination-inhibition (HI) test
measuring RV specific IgG antibody titers. This was first used for rubella
diagnosis in 1967 by Stewart and co-workers (for review see Cradock-Watson,
1991).
Later, enzyme-linked immunoassays (ELISA:s) have added both ease
and sensitivity to the antibody titration assays (Voller and Bidwell 1975).
Effort have been made on adding sensitivity and specificity to detect IgM
antibodies, and to replace the viral antigen by recombinant proteins or peptides
(Seppänen et al., 1991; Zrein et al., 1993; Grangeot-Keros and Enders 1997).
Further sensitivity to the diagnostic assays was achieved using time-resolved
fluoroimmunoassays (Meurman et al., 1982).
Concerning the sensitivity of detection a viral infection based PCR
diagnosis is of course superior to all other known methods. In PCR, the
detection of just a few copies of the viral RNA genome gives rise to an
amplified product (Ho-Terry et al., 1990; Bosma et al., 1995). The risk of
contamination and hence a false positive result could, however, be an obstacle
in a non-sterile environment.
Since the avidity of immunoglobulins to RV structural proteins seams
to reflect the time passed since infection (Mauracher et al., 1992; Hedman et
al., 1993), an avidity/affinity measurement of the RV-specific antibodies might
reveal the time of virus infection. At present  such diagnostic assays are not in
general use.
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1.5 Expression of Recombinant Rubella Virus Proteins
With the development of gene technology, recombinant constructs
containing different regions of the RV genome have been engineered. The very
high CG content of the RV genome (67% for the E1 protein) made for some
initial problems in the PCR of the RV genome (Cusi et al., 1992), but today
different RV constructs have been expressed in several different hosts .
Affinity tags have also been engineered to RV constructs, both for purification
and detection.
Bacterial (E.coli) expression is one of the most used system for
production of recombinant proteins. The host-genome is well known and yield
and protein trans-location can often be well controlled (for review see Baneyx,
1999). E.coli have been used for expression of RV derived constructs. Even
though bacteria lack glycosylation capabilities, these RV constructs have been
shown to essentially retain their antigenicity (Terry et al., 1989).
Mammalian expression systems have also been used for RV gene
expression, thus mimicking as closely as possible the naturally occurring RV
proteins. Here the approach has been either to use viral infection or transient
transfection of the cells. Both African green monkey ( CV-1, COS and Vero)
and hamster (Syrian golden hamster, baby kidney cells; BHK) cells have been
used for such expression studies(Sanchez and Frey, 1991; Hobman et al., 1994;
Qiu et al., 1994). In BHK cells virus-like particles (VLPs) containing the RV
structural proteins have been expressed. These VLPs have been helpful not
only in immunological studies but also in studying viral morphogenesis
(Garbutt et al., 1999).
Several groups have made use of the baculovirus expression vector
system (BEVS) for expression of RV constructs, showing processing and
antigenicity similar to native RV (Oker-Blom et al., 1989; Seppänen et al.,
1991; Cusi et al., 1994). Soluble forms of the envelope proteins as well as
affinity tagged constructs have been expressed (Seto et al., 1994). These
studies suggest that the BEVS is useful for studying individually the RV
proteins.
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1.6 The Baculovirus expression vector system
Baculoviruses are a family of insect viruses. Recombinant
baculoviruses are widely used for high-level expression of heterologoues
genes. The expressed genes are usually placed under the control of the
polyhedrin promoter of Autographa californica nuclear polyhedrosis virus
(AcNPV) or the Bombyx mori nuclear polyhedrosis virus (BmNPV). In nature
the virus produces high amount of the polyhedrin protein, as a protective shell.
The polyhedrin gene can be, in the laboratory environment, replaced by
another gene. The corresponding gene product is then, in most cases,
processed, modified and properly targeted, thus displaying its expected
properties (for review see: O’Reilly et al. 1992; Davis, 1995).
The baculovirus expression vector system (BEVS) combines many of
the advantages of other expression systems. With baculovirus mediated
expression in insect cells, high expression, sometimes reaching or surpassing
yields achieved in bacterial expression, can be obtained. Insect cells are also
capable of glycosylation and post-translational modifications similar to higher
eukaryotes (for review see Possee 1997). With the introduction of the method
of transposon-mediated insertion of the recombinant gene into a baculovirus
genome propagated in E.coli, construction of recombinant baculoviruses has
become relatively straightforward (Luckow et al., 1993).
Many proteins have been expressed utilizing the BEVS, ranging from a
single capsid protein to a glycosylated multisubunit complex, such as an ion-
channel (Kuusinen et al., 1995). Possibly the most complicated examples of
protein production using the BEVS could be the assembly of virus-like
particles using triple and quadruple expression vectors (Belyaev and Roy,
1993, Roy and Jones 1996).
Today, the baculovirus expression vector system is still mainly used for
expression of heterologous proteins in insect cells. Other uses of BEVS has
been as an insecticide (Cory and Bishop 1997) and more recently as a
mammalian cell transfer vector (reviewed in: Kost and Condreay 1999) and as
eucaryotic display vesicle (Mottershead et al., 2000).
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2. AIMS OF THE STUDY
In this study the primary goals were to produce and purify recombinant
RV proteins and to compare their antigenicity to authentic RV virus. Protein
expression studies were carried out both in small and large scale and different
purification schemes evaluated and optimized. The antigenicity of the purified
proteins was compared to authentic virus using a collection of patient serum
samples. This was initially analyzed in an ELISA type assay, later to be
replaced with a time-resolve fluorescence immunoassay.
Towards the end of the study we introduced the surface plasmon
resonance (SPR) method into our analysis. The focus of the SPR studies was
on establishing a model systems that could be used for diagnostic applications.
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3. MATERIALS AND METHODS
3.1 Plasmid Constructions
A plasmid containing the entire coding region of the RV structural
genes pGEM2-RV24S (Suomalainen et al., 1990) was used as the starting
material in all studies. First, a recombinant baculovirus containing the entire
24S transcription-translation unit of RV was produced. This was performed by
removing the 24S cDNA from pGEM2-RV24S and then inserting the 24S
cDNA downstream of the polyhedrin gene promoter into a linerized
baculovirus transfer vector (pVL1392) using standard cloning procedures
(Sambrook et al, 1989). The resultant plasmid was designated pVL1392-
RV24S. This construct was used in studies I, II and III.
In study IV the sequences coding for the extra-virion region of E1 and
E2 respectively, were amplified from pGEM2-RV24S using PCR (Saiki et al.,
1985). The E1 and the E2 coding sequences were first inserted into the SmaI
site of the plasmid pBluescript ks (Stratagene, La Jolla, CA) and then digested
with BglII/XbaI and BamHI/EcoRI respectively and ligated into the
appropriately cut plasmid pVTBac (Tessier et al., 1991). Thus yielding the
transfer plasmids pVTBac-E1 and pVTBac-E2.
In study V and VI the BAC-to-BAC Baculovirus Expression System
(Gibco-BRL, Grand Island, NY) was used. The sequence coding for the capsid
protein and the extra-virion region of the E1 was amplified by PCR from
pGEM2-RV24S and cloned into the BglII/XbaI sites of a pBluescript
derivative (pK410-1) containing sequences coding for the signal peptide of the
rat glutamate receptor GluR-D, followed by a FLAG epitope tag and a
carboxy-terminal polyhistidine (His6) tag (Kuusinen et al., 1995). The
resultant E1 sequence containing plasmid designated pK410-1E1sol, encoded a
soluble extra-virion form of the rubella virus E1 protein with amino and
carboxy terminal epitope tags.
The capsid coding sequence was further subcloned into the
NcoI/BamHI site of pK409-1 thereby omitting the signal sequence and the
FLAG-tag. pK409-1 is a pFASTBAC1 derivative which was used for the
generation of a recombinant baculoviruses via the BAC-to-BACTM system
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(Gibco-BRL). This system is based on the transposon-mediated insertion of
foreign genes into the baculovirus genome under transcriptional regulation of
the polyhedrin gene promoter (Luckow et al., 1993).The final plasmid product
designated pOB504-1 encoded the capsid protein with a carboxy polyhistidine
tag. The expression cassette from pK410-1E1sol was directly transferred to the
pK409-1 plasmid thus encoding for both the signal sequence and the FLAG-
tag as well as the carboxy polyhistidine tag. The resultant plasmids were
named pAcRVE1sol and pOB504-1. Sequencing of the constructs was
performed according to the protocol of the Sequenace (version 2.0) kit (USB,
Cleveland, OH).
3.2 Viruses
The plasmid pVL1392-RV24S was used for cotransfection with wild type
Autographa calfornica nuclear polyhedrosis virus (AcNPV) DNA into
Spodoptera frugiperda (Sf9) cells. The recombinant virus (VL1392-RV24S)
produced as a result of homologues recombination, was amplified by standard
procedures (Summers and Smith, 1987; O’Reilly et al., 1992) and stored at
4°C. This virus was used in study I, II and III.
Production of recombinant baculoviruses from pVTBac-E1 and pVTBac-E2
was performed as mentioned above using cotransfection of the transfer
plasmids and wild-type AcNPV DNA into Sf9 cells using a calcium phosphate
precipitation.
The expression cassette was transferred from the pBluescript
derivatives pFASTBAC1 derivatives pOB504-1 for the capsid protein and
pAcRVE1sol which was used for the generation of a recombinant
baculoviruses via the BAC-to-BACTM system (Gibco-BRL). The resultant
baculoviruses was designated vOB504-1 for the capsid protein and
AcRVE1sol for the E1.
3.3 Cell Culture and Infection of Cells
Lepidopteran Spodoptera frugiperda cells (Sf9; ATCC CRL1711,
Rockville, MD) were maintained as monolayer and suspension cultures at 27-
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28°C. In study IV Tricoplusia ni (High Five; Invitrogen, San Diego, CA)
cells were also used. Initially the Sf9 cells were grown in TNM-FH medium
(Sigma Chemicals, St. Louis, MO) supplemented with 2 mM L-glutamine, 10
% fetal calf serum and antibiotics (penicillin, streptomycin and fungizone). For
study VI only serum-free SF900 II medium (Gibco-BRL) was used.
For amplification of the viruses, cells were first grown either on 25 cm2
tissue culture flasks or in 250 ml Erlenmeyer flasks, at a density of 1,5 x 106
viable cells per ml, and infected with recombinant viruses with a multiplicity
of infection (MOI) of 0.5 plaque forming units (PFU) per cell. The extra-
cellular virus (ECV) was harvested two days post infection (p.i.). The
amplified virus was there after used for protein production. In all studies
infections with a MOI of at least 2 PFU were used. Study I, II and III were
performed using spinner flasks and study VI 2,8 l Fernbach flasks on orbital
shakers (130-135 rpm). Cells were collected at three days p.i. by low-speed
centrifugation (1000 x g) and if needed stored at -20°C.
In study IV and V bioreactors were utilized and therefore the viruses
were further scaled up by infections of 1000 ml of Sf9 cells, as described
above. The cells were first grown in 2,8 l Fernbach flasks on orbital shakers
and after reaching a density of 6 x 106 to 1 x 107 cells/ml, aseptically
transferred to a 10 l Biostat ECD bioreactor (B. Braun Biotech, Melsungen,
Germany) containing serum-free medium (Weiss et al., 1995a; Weiss et al.,
1995b).
The bioreactor had a surface aerator and two large-pitched blade
impellers. The speed was initially set to 49 rpm and subsequently raised as the
cell density increased. Thus maintaining the oxygen level at 40-45% of air
saturation. The pH was kept at 6,2 ± 0,5. The L-lactate and glucose
concentrations from the cell culture supernatant were analyzed using a YSI
Model 2000 glucose analyzer (Yellow Springs Instruments, Yellow Springs,
OH). The osmomolarity of the growth medium was determined by an
Advanced Model 3 MO Plus Micro Osmometer (Advanced Instruments Inc.,
Norwood, MA). The initial cell density was 7-8 x 105 cells/ml and cells were
grown until a density of 2,4 x 106 viable cells/ml was reached. Infection with
the recombinant baculoviruses was performed at a MOI of 1-5 PFU per cell. At
48 h (soluble E1 constructs) and 58 h (capsid construct) p.i. cells were
harvested, by filtration, using a Sartorius Benchtop Tangential UF system
(Sartorius GmbH, Göttingen, Germany) with 0,45-µm cellulose acetate
membranes. The recombinant viruses were collected from the supernatant
using polyester sulfone 100.000 MWCO membranes (Sartorius). Cells were
concentrated by centrifugation 1000 x g for 5 min and stored at -20°C.
24
3.4 Protein Purification
3.4.1 Immunoabsorbtion
Cytoplasmic extracts were prepared from cells infected with
recombinant baculoviruses containing the RV 24S cDNA (VL1392-RV24S).
Cells were resuspended in TNE buffer (10 mM Tris-HCl [pH 7,8], 150 mM
NaCl, 1 mM EDTA) containing 1% Triton X-100 and 0,2 mM
phenylmetylsulfonyl fluoride (PMSF), to a concentration of 10 x 106 cells/ml.
The cell suspension was incubated 30 min on ice and clarified by
centrifugation 5.000 x g, 10 min.
The immunoabsorbent was prepared by using CNBr activated
Sepharose 4B (Pharmacia AB, Uppsala, Sweden) and a protein G purified E1
specific monoclonal antibody 4E10 (I). The CNBr-Sepharose 4B was swollen
in 20 volumes of 1 mM HCl for 15 min, washed and equilibrated in coupling
buffer (0,2 M NaHCO3, 1,0 M NaCl, pH 8,0). The activated gel was mixed
with antibody 4E10 (0,25 mg / ml coupling buffer) at twice the gel volume.
Coupling was performed for 2 h, RT, using end-over-end rotation ( e-o-e).
Unbound antibodies were removed by discarding the supernatant after
centrifuging the gel slurry at 200 x g, 5 min. Remaining reactive groups were
blocked by incubation with 0,1 M Tris-HCl, pH 8,0, 2 h, RT. Finally, the gel
was washed free of reactants with 7 mM Na/K-phosphate buffer (pH 7,3) and
three cycles of washes with, first 0,1 M Na-acetate buffer (pH 4,0) with 0,5 M
NaCl and then 0,1 M Na2CO3 (pH 11,0) with 0,5 M NaCl.
The clarified cell-lysate was incubated with the anti-E1 coupled
Sepharose beads o/n, at 4°C, e-o-e. Lysate from 20 x 106 cells was incubated
per ml of gel. Following the absorption the gel was washed with 7 mM Na/K
phosphate buffer (pH 7,3) and absorbed proteins were eluted with 0,01 M
Na2CO3 with 0,005% CHAPS and 0,1 mM Thimerosal (pH 11,0).
3.4.2 Concavalin A Affinity Chromatography
Cells infected with viruses encoding the soluble E1 construct (VTBac-
E1) were harvested and concentrated by centrifugation as mentioned
previously and washed with ice cold PBS. Cytoplasmic extracts were prepared
by lysing the cells with TNE buffer containing 1% Triton X-100 and 0,2 mM
phenylmetylsulfonyl fluoride (PMSF). The soluble extract was sonicated (3 x 5
s) and clarified by centrifugation for 10 min 10 000 x g, at 4°C. The
supernatant fractions were thereafter ammonium sulfate precipitated.
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Ammonium sulfate saturated solution was added step-wise using 10%
salt increasement to the cytoplasmic extract. The protein precipitation was
performed at 4°C, for 2 h. The precipitates were collected by centrifugation at
12 000 x g, at 4°C. Precipitate fractions used for Concavalin A affinity
chromatography were dissolved in start-buffer (0,5 M NaCl, 20 mM Tris, 1
mM CaCl2, 1 mM MgCl2, pH 7,4) and further dialyzed against this buffer, o/n,
4°C.
The Concavalin A Sepharose 4B column (Pharmacia) was equilibrated
with start-buffer containing 0,01% Triton X-100. The recombinant E1
containing extract was exposed to the column by continuos recirculation of the
sample through the column (1 ml/min), for 12 h, at 4°C. There after the
column was thoroughly washed with the same buffer. Weakly bound
glycoproteins were eluted using a gradient of methyl-α-D-mannoside. Elution
of E1 from the resin was performed by including 10 mM EDTA in the buffer.
3.4.3 Immobilized Metal-Ion Affinity Chromatography
An agarose gel with Ni2+ ions immobilized with nitrilotriacetate (NTA;
Qiagen Inc., Chartsworth, CA) was used for purification of the polyhistidine-
tagged proteins by immobilized metal-ion affinity chromatography (IMAC;
Janknecht et al., 1991; Kuusinen et al., 1995). Initially, frozen cell pellets were
disrupted by resuspension in ice-cold lysis buffer (0,5 M NaCl, 10 mM Hepes,
10 % (v/v) glycerol, 0,1 mM EDTA, 5 mM MgCl2, 5 mM imidazole, 75 µg /
ml PMSF, 1 % (v/v) Triton X-100, pH 7,8), at 2 x 107 cells/ml buffer. The lysis
was performed on ice for 1 h with gentle mixing and the crude cell lysate
clarified by centrifugation (10 000 x g) for 15 min at 4°C. The supernatant was
thereafter incubated with the Ni2+-NTA resin o/n, e-o-e, at 4°C. Prior to the
incubation the resin was equilibrated in lysis buffer.
Weakly bound proteins were washed off the resin with lysis buffer (10
x resin volume). More strongly bound proteins were eluted by a step-wise
increasing gradient of imidazole (10 and 40 mM) in end-buffer (0,5 M NaCl,
20 mM Hepes, 20 % (v/v) glycerol, 0,1 mM EDTA, 5 mM MgCl2, 75 µg / ml
PMSF, 1 % (v/v) Triton X-100, pH 7,8). The recombinant histidine-tagged
proteins were eluted with end-buffer containing 250 and 500 mM imidazole.
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3.4.4 Anti-FLAG M1 Affinity Chromatography
E1 protein samples containing both a polyhistidine and a FLAG-tag
were pooled and purified by affinity chromatography (AC) using an anti-
FlagTM M1 Affinity Gel (Sigma-Aldrich, St.Louis, MO). Prior to exposure to
the affinity matrix E1 fractions pooled from the IMAC were dialyzed against
TBS containing 2 mM CaCl2 and 1% Triton X-100. The affinity matrix was
also equilibrated in the same buffer. Binding of E1 to the M1 gel was
performed o/n, e-o-e, at 4° C. Contaminants were washed off the resin with
several column volumes washes of the starting buffer. FLAG-tagged E1
protein was eluted off the column with TBS containing 2 mM EDTA and 0,1
% Triton X-100. Eluted fractions used in surface plasmon resonance studies
were dialyzed against TBS containing 0.2% BSA and 0.05% Tween 20.
3.5 Protein Analysis Assays
3.5.1 Protein Concentration Assay
Protein quantity determination were carried out either using the method
of Bradford (Bradford 1976) or a bicinchonic acid assay (Pierce, Rockford,
IL). The Bradford assay was performed in 1 ml volumes and with BSA as a
reference. The Pierce BCA assay was performed in a microtiter plate format,
as described by the manufacturer, also utilizing BSA as a standard.
3.5.2 SDS-PAGE and Immunoblot Analysis
All samples were denatured with Laemmli sample buffer (Laemmli,
1970) and boiled for 3 min. The protein samples were separated on 10 % SDS-
polyacrylamide slab gels. The total protein content was visualized by
Coomassie brilliant blue or silver salt staining according to standard protocols
(Sambrook et al., 1979). For immunoblotting proteins were transferred to
nitrocellulose membranes (Towbin et al., 1979). The membranes were blocked
with 2% milk powder. Detection was performed essentially according to
published procedures (Oker-Blom et al, 1989; Seppänen et al., 1991).
The following primary antibodies were used; 1) a rabbit polyclonal RV
antiserum, 2) a human convalescent serum, 3) a mouse monoclonal capsid
specific antibody (Wolinsky et al, 1991), 4) a mouse monoclonal polyhistidine-
tag specific antibody (His-Tag antibody; Dianova GmbH, Hamburg,
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Germany), 5) a mouse monoclonal FLAG tag specific antibody (M1 anti-
flagTM antibody; Eastman Kodak).
Visualization was performed with the following secondary antibodies
according to the manufacturers instructions; a) horseradish peroxidase (HRP)-
conjugated goat-anti rabbit antibodies (Caltec Laboratories, San Francisco,
CA), b) alkaline phosphatase (AP)-conjugated goat-anti rabbit antibody (Bio-
Rad, Richmond, CA), c) alkaline phosphatase (AP)-conjugated goat anti-
human IgG + IgM + IgA antibodies (Zymed Inc., San Francisco, CA), d)
alkaline phosphatase (AP)-conjugated goat-anti mouse antibodies (Bio-Rad).
Molecular weight markers where from Bio-Rad and Pharmacia.
Partially purified rubella virus was also used as a control (Toivonen et al.,
1983).
3.5.3 ELISA
Partially purified RV or purified recombinant E1 was diluted in carbonate-
bicarbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9,6), to a
concentration of 2 µg/ml. Microtiterplates were coated with 50 µl of the
antigen solution, o/n, at 4°C. The plates were thereafter washed with PBS –
0,05% Tween 20 and blocked for 1 h, at RT, with PBS -1% BSA. Human sera,
of different dilutions, in PBS –1% BSA, were added and incubated for 2 h, at
RT. After this incubation the plates were washed four times as above. For
detection of human antibodies a HRP conjugated goat anti-human antibody
(Caltac Laboratories) was used, diluted 1:3000 in PBS –1%BSA, and
incubated 1 h, at RT. The incubation was followed by four washes and
detection with chromogen solution (0,66 mg of o-phenylenediamine per ml of
0,1 M citric acid –Na phosphate buffer [pH 5,0] and 0,1 % H2O2). The color
reaction was stopped after approximately 5 min with 1 M HCl and the optical
density measured at 492 nm.
3.5.4 Time-Resolved Fluoroimmunoassays
The diagnostic study (III) analyzing detection of RV-specific IgM
antibodies was performed using time-resolved fluoroimmunoassays with the
DELFIA system (Soini and Lövgren, 1987; Wallac Oy, Turku Finland).
Microtiterplates were coated with either purified recombinant E1 or RV, at 2
µg/ml in PBS, o/n, at 4°C. The plates were blocked and washed as described
for the ELISA. Human serum samples were diluted 1:100 in PBS –1%BSA.
Bound IgM antibodies were detected by an Eu3+-labeled anti-human IgM
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antibody (anti-IgM clone 7408; Medix Biochemica Oy, Kauniainen, Finland).
Labeling of the secondary antibody was performed according to the
manufacturers instructions (Hemmilä, 1988; Wallac Oy). Enhancement of the
fluorescence and measurement of the signal on a DELFIA research
fluorometer was performed according to the manufacturers protocols (Wallac
Oy).
3.5.5 Surface Plasmon Resonance
The BIAcoreTM Upgrade biosensor apparatus (Biacore AB, Uppsala,
Sweden) was used for the surface plasmon resonance (SPR) experiments.
Results were analyzed using the BIA Evaluation v. 2.1 software (Biacore AB).
The purified histidine-tagged capsid and E1 protein were immobilized via the
His-tag to a NTA sensor chip using essentially conditions suggested by the
manufacturer (Biacore AB).
Initially the sensor chip surface was equilibrated with eluent buffer
(10mM HEPES, 0,15 M NaCl, 50 µM EDTA, 0.005% Surfactant P20, pH 7,4)
with a flow rate set to 5 µl / min. Ni2+ was thereafter loaded to the sensor chip
surface by injection of 40 µl nickel solution (500 µM NiCl2 in eluent buffer).
For immobilization the capsid protein was diluted five-fold and the E1 protein
two-fold in ligand buffer (10mM HEPES, 10 mM CaCl2, 10 mM MgCl2, 0,15
M NaCl, 0.005 % Surfactant P20, pH 7.4). The final concentration of the
purified proteins was approximately 50 µg/ml.
The protein solution was injected (200 µl volume) over the Ni2+ -NTA
surface. The capsid specific monoclonal antibody (C-2; Wolinsky et al., 1991)
was diluted fourfold in ligand buffer whereas the FLAG-tagged E1 specific M1
anti-flagTM antibody (Sigma) was diluted to a final concentration of 10 µg / ml
in ligand buffer.
As one of the controls for the studies with the capsid protein, a
nonrelevant (a soluble RV E2 with a polyhistidine tag) protein was expressed,
purified and immobilized in a similar manner. The control experiments for the
E1 protein were designed to demonstrate the sensitivity of the assay. Therefore
we used a ligand buffer without CaCl2. In these experiments washing of the
sensor chip surface was also performed in the absence of CaCl2. In this way we
were able to study the binding of the M1 antibody to the FLAG-tag both in the
presence, and in the absence of, Ca2+. Control experiments with irrelevant
immobilized proteins (the capsid protein lacking a FLAG tag) and antibodies
(a non-E1 specific monoclonal mouse antibody) using normal ligand binding
conditions were also performed.
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4. RESULTS
4.1 Recombinant Constructs
The recombinant viruses produced and used in studies I-IV were
formed as a result of homologous recombination between a transfer plasmid
and baculoviral DNA. In study V and VI transposon-mediated recombination
was used for inserting the RV protein coding sequences into the baculovirus
genome. RV sequences were in all cases inserted under the transcriptional
regulation of the polyhedrin gene promoter. Made DNA constructs were also
sequenced.
Recombinant baculoviruses encoding the following constructs were
produced: 1) the p110 polyprotein encoding the RV structural proteins
(VL1392-RV24S), 2) a truncated soluble form of the E1 (VTBac-E1), 3) a
truncated soluble form of the E2 (VTBac-E2), 4) a polyhistidine tagged capsid
protein (vOB504-1), 5) a FLAG and polyhistidine tagged soluble E1
(AcRVE1sol) (Figure 5).
4.2 Expression in Insect Cells
Cells grown in spinner flasks or in Fernbach flasks were collected 2 – 3d p.i.
The growth and the morphological state of the cells were visually monitored
using phase contrast microscopy. Cells were collected before any prominent
occurrence of cell death. Often cells were seen to have a swollen “infected”
morphology, before collection. The truncated soluble form of the E1 (VTBac-
E1) and the polyhistidine tagged capsid protein (vOB504-1) were expressed in
10 l bioreactors. Growth of the cells was followed both post planting (p.p.) and
post infection (p.i.). The speed of the pitched blade impellers (rpm) was
adjusted according to the oxygen level, which was maintained at 40 – 42% of
air saturation. The cell density was also followed (IV: Table 1; V: Table 1).
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A) the p110
B) the extra viral  part of E1, preceded by the melittin signal sequence
C) the extra viral part of E2, preceded by the melittin signal sequence
D) the capsid protein with a polyhistidine tag at the carboxy
E) the extra viral  part of E1 preceded by a Flag-tag and with a
polyhistidine tag at the carboxy end
Figure 5. Recombinant RV constructs. Recombinant baculoviruses were obtained
using homologues recombination for constructs A) to C). Transposon-mediated insertion
was used for constructs D) and E). These two constructs were preceded by the signal
sequence for GluR-D glutamate receptor subunit.
C E2 E1
Melittin-ss
Melittin-ss
6xHis
6xHis
GluR-ss
FLAG
E1 -soluble region
E2 -soluble region
C
E1 -soluble region
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Cells were infected 2 d p.p., at a concentration of 2,0 – 2,4 x 106 cells
per ml, and cell division stopped following infection. At 48 h p.i. (E1) and 58 h
p.i. (capsid), prior to the occurrence of cell death, cells were collected.
Expression of RV-specific proteins was detected by SDS-PAGE and
immunoblot analysis.
4.3 Protein Purification
4.3.1 Immunoabsorbtion
The E1 protein expressed using the RV p110 encoding recombinant
baculovirus VL1392-RV24S was purified with Sepharose beads coupled to the
E1 specific antibody 4E10. Attached proteins were eluted using alkaline
conditions and the purified fractions were pooled and analyzed by Coomassie
blue staining of SDS-PAGE gels and immunoblotting. Immunoblotting with a
polyclonal rabbit anti-RV serum revealed a RV-specific protein of the
expected size of the E1 protein. Coomassie blue staining of these fractions
demonstrated the high purity of the E1 protein fractions (I: Figure 1).
Quantification of the level of protein using the method of Bradford showed
that this final preparation had a concentration of 35 – 50 µg purified protein /
ml elution buffer. Giving a total of 600 - 800 µg of purified protein / l of cell
culture medium.
4.3.2 Concavalin A Affinity Chromatography
Soluble E1 expressed by infection of insect cells in a 10 l bioreactor with the
VTBac-E1 virus was prior to  Concavalin A affinity chromatography enriched
by ammonium sulfate precipitation. The major portion of the total E1 protein
was found to precipitate in 20 % ammonium sulfate. This was determined by
SDS-PAGE and Coomassie blue staining as well as immunoblotting using
polyclonal rabbit anti-RV serum (IV: Figure 4). The ability of this glycan-
specific purification method to purify the E1 protein to homogeneity was
shown by immunoblotting (IV: Figure 5). The purified protein was shown to
migrate as expected from the calculated molecular weight (52 kDa).
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4.3.3 Immobilized Metal-Ion Affinity Chromatography
The polyhistidine tagged capsid protein was expressed in a bioreactor
using the recombinant baculovirus vOB504-1. The FLAG and polyhistidine
tagged soluble E1 (AcRVE1sol) was expressed in a smaller scale using
Fernbach flasks. The immobilized metal-ion affinity chromatography (IMAC)
was performed using 5 mM imidazole in the initial binding stage and thereafter
a stepwise gradient up to 500 mM. The purification profiles of the recombinant
protein were studied by SDS-PAGE and Coomassie brilliant blue staining  as
well as immunoblotting (V: Figure 3 and 4).
Purification of the capsid construct revealed an elution profile where
the majority of the capsid protein eluted at 250 – 500 mM imidazole. Protein
quantitation of the different fractions was determined using a bicinchonic acid
assay. Protein concentrations of more than 1 mg purified protein / ml elution
buffer was achieved using these conditions. A total of 5 mg of purified capsid
protein could be obtained from 1 l of cell culture.
The IMAC of the epitope tagged E1 protein resulted in a partially
purified product. Protein contaminants and some putative degradation products
of the E1 were seen in the 50 mM imidazole fractions. In 250 mM imidazole
elution the E1 protein product was shown as a large homogenous band,
although some putative degradation were visible (VI: Figure 1).
4.3.4 Anti-FLAG M1 Affinity Chromatography
In order to obtain pure epitope tagged E1 protein the IMAC elutants
were pooled and further purified by affinity chromatography (AC) using the
Anti-FLAG M1 Affinity Gel. The purification was analyzed by
immunoblotting and silver staining of SDS-PAGE gels (VI: Figure 1). The
immunoblot shows a large homogenous band corresponding to the expected
size of E1. Some higher molecular weight complexes as well as some smaller
molecular weight proteins were also visible. These were speculated to be
multimeric E1 complexes and breakdown products, respectively, as they are
antibody reactive.
The silver stained SDS-PAGE revealed that the contaminating proteins
were removed in the flow-through fractions and the eluted fractions showed an
E1 protein sample of high purity. The eluted fractions of 1 ml volume usually
contained protein at concentrations of 30 – 50 µg / ml buffer, determined by a
bicinchonic acid assay. In the experiment shown in study VI the elution was
terminated after 6 eluted fractions, giving roughly 200 – 300 µg purified
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protein from 1 l cell culture. However the M1 affinity matrix showed a very
slow dissociation of the E1 protein after chelating the Ca2+ ions present and
elutions could sometimes be extended to 10 - 20 fractions with decreasing
protein concentrations detectable in each fraction.
4.4 ELISA
The antigenicity of the E1 protein, purified by immunoabsorbtion, was
tested with RV-specific IgG from human convalescent sera was studied using
an ELISA. In the ELISA the antigenicity of the E1 was compared with
authentic RV. Two different RV-negative and two different RV-positive serum
samples were tested using a dilution serie (I: Figure 2). The optical density at
492 showed clear differences between the positive and the negative samples.
The purified E1 was demonstrated to have an antigenicity similar to the
authentic RV.
4.5 Time-Resolved Fluoroimmunoassays
The antigenicity of the purified E1 and authentic RV was analyzed in a
correlation study using time-resolved fluoroimmunoassays (TR-FIA) with the
DELFIA system. The two different antigens were incubated with 64 human
serum samples from patients with recent or past rubella infections. RV-specific
IgM antibodies were detected with murine anti-human IgM monoclonal
antibodies labeled with Eu3+. The measured fluorescence from the two assays
were compared (III: Figure 2). The performed assays were shown to have a
positive correlation of r = 0,843, indicating similar antigenicities of the two
antigens. The mean fluorescence values were shown to be 9,5 % higher in the
TR-FIA where authentic RV was used as the antigen.
4.6 Surface Plasmon Resonance
The IMAC purified histidine tagged capsid protein as well as the IMAC anti-
FLAG-AC purified epitope tagged soluble E1 protein were used in surface
plasmon resonance (SPR) analysis. Dextran matrix sensor chips containing
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covalently coupled NTA were used. Ni2+ was bound to the NTA linker and the
polyhistidine tagged recombinant proteins were immobilized to the Ni2+
charged matrix.
Following immobilization of the capsid protein and subsequent washes,
a monoclonal capsid specific antibody (C-2) was injected over the sensor chip
surface. Binding of a protein to the sensor chip is detected by an increase in
response units, which is relative to the change of mass on the surface . The
complete analysis scheme includes the loading on Ni2+ to the matrix,
immobilization of the capsid protein and binding of the C-2 antibody to the
capsid. All steps were followed by washing where the resultant baseline shows
the actual change in bound mass and not just the reflective index of the buffers
used. The specificity of the C-2 antibody capsid binding is visualized
graphically by subtracting the obtained response units from a control
experiment were the C-2 antibody was injected over an irrelevant antigen (V:
Figure 2).
The epitope-tagged E1 protein was immobilized to the NTA matrix as
described above for the capsid protein. Here the Ca2+ dependent binding of the
M1 antibody to the FLAG-epitope was utilized. The M1 antibody was injected
over the E1 immobilized on the sensor chip surface in the presence and in the
absence of CaCl2 (VI: Figure 3). Here a clear difference in the binding of the
antibody to the E1 is demonstrated.
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5. DISCUSSION
The information obtained about the molecular biology of rubella virus
(RV) has severely lagged behind the Alphaviruses. This situation has mainly
been due to the fact that Alphaviruses has been widely studies as a model virus
and to the fact that no good animal model system for rubella infection is
available and because some Alphaviruses have also been extensively studied as
tools for viral biotechniques (e.g. gene therapy and viral-mediated gene
expression systems (Schlesinger and Dubensky, 1999)). Several striking
differences in the assembly and budding of the viruses have been found. The
RV capsid also lacks the characteristic serin protease domain needed for
Alphavirus polyprotein processing (Melancon and Garoff, 1987; Clarke et al.,
1988). Both the structural and the non-structural proteins differ in organization,
number and some functions between the Alphaviruses and RV.
Alphaviruses have a very broad host range including invertebrates and
vertebrates. Several of the different host cell receptors interacting with the
viruses have also been identified (for review see Strauss and Strauss, 1994).
Studies focusing on the Alphavirus structure have also revealed the role of
different sites in the structural proteins (e.g. amino acid residues responsible
for interactions between the structural proteins (Lee et al., 1996; Skoging et al.,
1996)).
The evident differences between RV and the Alphaviruses shows that
assumptions, of structure and function or on the viral biology of RV, cant be
made based on information obtained from the Alphaviruses. Since RV is a
human pathogen an effort to understand the biology of the virus would not
only give information that could be found valuable for other human pathogens,
but it would also have significant medical implications.
A good starting point when trying to gain information about a protein is to
have a system for producing large amounts of the desired molecule with a high
degree of purity and native folding. This has been the main aim throughout this
study. We started by expressing the structural polyprotein (p110) in insect cells
in spinner flask culture. The E1 protein was purified from the cytoplasmic
extract using affinity chromatography with a monoclonal E1 specific antibody
(I). The purification process was optimized so that no contaminants were
visible in Coomassie blue stained SDS-PAGE gels. One consideration was
whether the glycosylation of the E1, in insect cells, would give rise to a native
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folded protein. This was partially answered in a earlier correlation study where
baculovirus-expressed envelope proteins were compared to the authentic virus
(Seppänen et al., 1991). Another concern was whether the E1 protein would
retain its antigenicity after purification. This we studied in an ELISA with four
serum samples and authentic RV as a reference. In this way we were able to
show clear similarities between our assays (I).
Different diagnostic assays for the detection of RV infection have been
widely studied (reviewed in Cradock-Watson, 1991). Most serological systems
are based on whole authentic RV, but other methods such as peptide antigen
and RV-like particle based EIA assays (Bosma et al., 1995; Grangeot-Keros
and Enders, 1997) have also been developed. Development of an ELISA-type
RV diagnostic kit has from time to time been on the development plan in
several clinical companies. To base a diagnostic kit on a recombinant protein
would have the obvious advantage of being non-infectious and could be
produced and purified in large-scale making it very cost efficient. The
diagnostic potential of our purified E1 protein was briefly studied with an
ELISA-type assay (I) and more in detail using TR-FIA (III).
The TR-FIA assay comparing the interaction of IgM antibodies with
the recombinant E1 or authentic RV was set up for three main reasons. First,
we wanted to see how our purified protein would perform in a correlation
study compared to authentic RV. Here we were able to detect a strong
correlation between the assays, suggesting that the presented scheme could be
worth investigating further for its possibility to function as a diagnostic assay
for detecting RV infection. Second, we were interested in setting up an IgM
detecting assay since IgM is the primary response to an infection. We were
able to show that RV specific IgM antibodies could easily be detected. Thirdly,
we wanted to see if a TR-FIA in the DELFIA format would give the assay
the needed sensitivity to obtain detectable differences between the different
serum samples. In some initial studies with a conventional type EIA assay this
had not been achieved. Here, we were able to show clear differences between
the serum samples, revealing the sensitivity of the TR-FIA.
Although the initial goals set up for the diagnostic assay were met,
several questions concerning the validity of the assay and suggestions for
further developments were raised. One obvious difficulty was to set the limit
for determination if a recent infection had occurred or not. This difficulty was
as clear in our control assay, showing that only one type of assay might not be
sufficient for determination of an infection. Another problem was that although
we found a strong positive correlation between the assays some individual
discrepancies were seen. Whether these were due to cellular protein
contaminants in our purified E1 sample giving too high response in some
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samples, or the lack of the E2 and the capsid giving too low a response in the
recombinant assay, remains to be studied. One shortcoming of the recombinant
assay was thought to be the relatively harsh alkaline purification and the
partially denaturing process of coating microtiterplates with the E1. Therefore,
further studies were designed so that affinity tags in our recombinant
constructs would allow a more gentle purification protocol and an affinity-tag
mediated immobilization of the recombinant constructs.
As mentioned earlier, one requirement for studying a protein is to
obtain large amounts of the molecule in a purified form. Therefore our next
aim was to scale-up the baculovirus expression system into a 10 l bioreactor.
At this point we had already successfully scaled up our expression from
spinner flasks (100 – 600 ml) to Erlenmeyer flasks and 2,8 l Fernbach flasks.
When scaling up the cell culturing, we focussed on amplifying our
recombinant viruses, as well as keeping the oxygen level in the cell culture
sufficient throughout the study. Viruses were in all our studies where proteins
are produced, used in excess and the speed of the bioreactor impellers was
adjusted to maintain the oxygen level. Following these guidelines we faced no
large obstacles in our scaling-up and expression of the recombinant proteins
remained at a similar level compared to small-scale cell culturing (IV, V).
Therefore we concluded that our expression scheme was favorable and can be
widely recommended.
Two affinity epitope tags were introduced in order to provide easy and
gentle purifications of the proteins and to obtain a site for immobilization of
the proteins in interaction assays. The polyhistidine-tag binds with high affinity
to divalent cations. Using this tag we were able to obtain a high affinity
complex containing our recombinant histidine-tagged protein and a Ni2+-NTA
agarose matrix. The great advantage compared to antibody utilizing affinity
chromatography is that not only can the affinity complex be achieved in most
buffers, but also disruption of the formed complex can be achieved by
competitive elution with imidazole, therefore eluting the recombinant protein
using gentle conditions. Another advantage is the high capacity of the Ni2+-
NTA affinity matrix, giving a strong concentration effect. Using this scheme
we were able to show a simple and gentle one-step purification scheme of the
polyhistidine-tagged capsid protein (V).
Using the same one-step IMAC purification scheme we were not able
to achieve the same high purity of a histidine-tagged E1. Whether this was due
to some general feature of glycoproteins or some E1 specific characteristic,
was not further studied. To this E1 construct we had, however, engineered a
second affinity tag, the FLAG-tag. The eight amino acid FLAG-epitope has
been shown to bind to an antibody (M1) in a calcium-dependent manner.
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Utilizing this characteristic feature of the M1 antibody, the E1 could be
immobilized to a M1 antibody containing affinity matrix, in the presence of
Ca2+ ions. Elution of the E1 was performed by chelating the Ca2+ ions with
EDTA. Using this purification scheme a gentle environment could therefore be
obtained during the whole purification protocol (VI).
A surface plasmon resonance (SPR) study of the purified protein using
the BIAcore equipment was chosen for several reasons. First, the NTA sensor
chips gave us a surface for immobilization of our protein via the affinity tag,
therefore avoiding a partial denaturation of the protein which occurs when
coating directly to microtiterplates. Secondly, we wanted to introduce the idea
of a SPR technique in RV diagnostic studies. By showing some example
studies we hope that the SPR technique may be found useful in antibody
affinity and avidity studies determining the onset of rubella infection.
With the capsid protein the SPR study was performed simply to show
that all critical steps of the assay could be performed. The immobilization of
the capsid protein was studied and the mechanism of the interaction between
the capsid and a monoclonal antibody was visualized. Here we found that our
assay should give a good starting point specific for the capsid, for further
studies of interactions between antibodies and viral proteins. Since this study
was performed the manufacturer recommends higher flow-rates to be used in
kinetic studies. For such studies we therefore also recommend higher flow-
rates so that possible rebinding of the antibody could be ruled out (V).
At present SPR studies are performed as single experiments. However,
in the future the biosensor technique might have potential for routine
diagnostics. This would require more simple experimental schemes, with
several tests performed at once. This could possibly be performed with
resonance mirror (RM) biosensors which today operate in a cuyvette format
instead of a flow cell on a sensor chip.
From our TR-FIA analysis, recognizing RV specific IgM antibodies,
we have seen the difficulty to determine between a positive and negative
response. Therefore we decided on a new approach to study our recombinant
E1 protein with the BIAcore. Instead of just confirming the research analysis
scheme obtained for the capsid we tried a more challenging approach. In the
E1 SPR study, we relied on the specific characteristics of the M1 anti-FLAG
antibody. The M1 antibody binds to the FLAG epitope in the presence of Ca2+.
However, it is also generally known, both from immunoblotting and ELISA
studies, that when using normal research grade buffers the M1 binds to the
FLAG epitope also in the absence of Ca2+. This binding occurs, naturally, to a
much lower level. By using a research scheme utilizing the clear positive
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binding of M1 in the presence of Ca2+ and the more undefined binding of M1
in the absence of Ca2+, we tried to create a system that would mimic the natural
occurrence of RV-specific serum antibodies. We were able to show clear
differences in the M1 binding, depending on the presence of Ca2+, indicating
that the SPR system is sensitive enough for RV antibody interaction studies
(VI).
It is evident that biosensors could be useful in diagnostic studies. The
equipment today is, however, more suitable for individual experiments than for
screening of large amounts of samples. The use of automatic systems with an
open detection cuyvette or microtiterplate could however change this. The
power of screening for multiple infections in each sample might often be
performed using PCR diagnostics, but determination of the onset time of the
infection could be followed up by SPR studies. We also see the need for simple
ELISA type assays to be used in less well-equipped laboratories and to be
produced in a cost efficient matter.
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6. CONCLUSSIONS AND FUTURE PERSPECTIVES
In this study we demonstrate that RV structural proteins, expressed by
recombinant baculoviruses in insect cells, show similar characteristics
compared to the authentic viral proteins. Large-scale expression of
recombinant RV proteins could be achieved and proteins purified with or
without affinity tags. Since no clear activity assay is available for RV proteins
the native state of the proteins was studied using antibody interaction assays
and correlation's calculated.
We were able to show how different RV structural protein variants
could successfully be expressed and purified. The diagnostic potential of the
E1 protein was also analyzed. The SPR analysis technique was also introduced
to RV protein analysis.
In the future there are at least three obvious paths to follow from the
results presented in this study. First, the protein production and purification
schemes presented provide the tools that could be used to study the basic
biology of the virus. With large amounts of purified protein structural aspects
as well as virus-cell interactions could be studied. A second path is the
development of a RV diagnostic kit using recombinant RV proteins. Different
concentrations of a mixture of E1, E2 and the capsid protein could be used in
the microtiterplate format. Immobilizing the proteins using different linkers or
affinity tags could be studied and different conditions for IgG and IgM analysis
could be tested. Different visualization assays could also be studied and
compared (e.g. ELISA vs. TR-FIA). Finally, the SPR studies should be further
developed. A scheme for gathering kinetic data, not only from monoclonal
antibody studies, but also from serum samples should be developed.
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